Combination therapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (interferon gamma and camrelizumab) given before surgery for a certain type of esophageal cancer. It aims to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a confirmed diagnosis of esophageal squamous cell carcinoma
- Cancer must be at a specific stage (T1b-3, N+, M0)
- Be in good overall health (ECOG score 0-1)
- Have adequate bone marrow, liver, kidney, blood clotting, and thyroid function
- Not have active autoimmune disease, require immunosuppressive therapy, have uncontrolled organ disease or active infection, or be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial is testing a combination of two drugs (cadonilimab and anlotinib) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests two drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer) and palbociclib (a targeted therapy that stops cancer cells from growing)—given before surgery for esophageal cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
Hear when a new Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.